Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLK Allakos	$0.33	$0.33	$0.22 ▼ $1.56	$29.74M	0.15	1.23 million shs	N/A
FGEN FibroGen	$7.52 +2.7%	$6.96	$4.50 ▼ $38.25	$30.38M	0.74	75,634 shs	30,407 shs
NKTR Nektar Therapeutics	$24.14 +1.4%	$14.78	$6.48 ▼ $37.38	$299.58M	0.94	511,026 shs	957,323 shs
SAGE Sage Therapeutics	$9.13 -0.4%	$7.78	$4.62 ▼ $13.47	$571.73M	0.29	1.33 million shs	1.62 million shs
UTHR United Therapeutics	$298.16 +1.7%	$300.99	$266.98 ▼ $417.82	$13.45B	0.53	443,298 shs	324,808 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLK Allakos	0.00%	0.00%	0.00%	+1.89%	-61.87%
FGEN FibroGen	-4.81%	+30.25%	+10.95%	+5.48%	-72.38%
NKTR Nektar Therapeutics	-2.50%	+4.71%	+177.07%	+161.48%	+13.33%
SAGE Sage Therapeutics	+0.22%	+0.11%	+36.87%	+24.42%	-22.29%
UTHR United Therapeutics	-1.49%	-0.40%	+3.49%	+2.82%	-10.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLK Allakos	3.3283 of 5 stars	3.1	0.0	4.7	0.0	2.5	1.3
FGEN FibroGen	4.6929 of 5 stars	3.3	4.0	4.7	3.8	3.3	0.6
NKTR Nektar Therapeutics	4.0188 of 5 stars	3.4	2.0	4.2	3.1	2.5	0.0
SAGE Sage Therapeutics	3.4114 of 5 stars	2.0	4.0	4.1	1.8	1.7	0.6
UTHR United Therapeutics	4.9872 of 5 stars	4.3	5.0	4.6	3.4	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLK Allakos	2.25	Hold	$2.00	507.72% Upside
FGEN FibroGen	2.50	Moderate Buy	$250.00	3,224.47% Upside
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	265.92% Upside
SAGE Sage Therapeutics	1.94	Reduce	$8.75	-4.20% Downside
UTHR United Therapeutics	2.69	Moderate Buy	$383.08	28.48% Upside

Current Analyst Ratings Breakdown

Latest NKTR, FGEN, UTHR, ALLK, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$348.00 ➝ $328.00
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
7/8/2025	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$350.00 ➝ $330.00
6/30/2025	UTHR United Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$410.00 ➝ $385.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLK Allakos	N/A	N/A	N/A	N/A	$1.93 per share	N/A
FGEN FibroGen	$29.62M	1.03	N/A	N/A	($50.89) per share	-0.15
NKTR Nektar Therapeutics	$98.43M	3.04	N/A	N/A	$4.94 per share	4.89
SAGE Sage Therapeutics	$47.40M	12.06	N/A	N/A	$7.60 per share	1.20
UTHR United Therapeutics	$2.88B	4.67	$28.45 per share	10.48	$144.34 per share	2.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLK Allakos	-$185.70M	-$1.32	N/A	N/A	N/A	N/A	-140.87%	-86.22%	8/6/2025 (Estimated)
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
NKTR Nektar Therapeutics	-$118.96M	-$9.60	N/A	N/A	N/A	-152.49%	-329.54%	-55.24%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.90	10.85	6.51	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest NKTR, FGEN, UTHR, ALLK, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ALLK Allakos	-$0.24	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	FGEN FibroGen	-$0.09	N/A	N/A	N/A	$2.88 million	N/A
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.89	N/A	N/A	N/A	$802.13 million	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLK Allakos	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLK Allakos	N/A	6.08	6.08
FGEN FibroGen	N/A	2.02	1.98
NKTR Nektar Therapeutics	N/A	3.24	3.24
SAGE Sage Therapeutics	N/A	9.13	9.13
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLK Allakos	84.64%
FGEN FibroGen	72.71%
NKTR Nektar Therapeutics	75.88%
SAGE Sage Therapeutics	99.22%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALLK Allakos	16.12%
FGEN FibroGen	1.98%
NKTR Nektar Therapeutics	3.71%
SAGE Sage Therapeutics	5.50%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLK Allakos	190	90.38 million	74.94 million	Optionable
FGEN FibroGen	570	4.04 million	3.96 million	Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.95 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

NKTR, FGEN, UTHR, ALLK, and SAGE Headlines

Recent News About These Companies

United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

July 16 at 7:00 AM | businesswire.com

Envestnet Asset Management Inc. Increases Stake in United Therapeutics Corporation (NASDAQ:UTHR)

July 16 at 3:43 AM | marketbeat.com

Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks

July 15 at 8:37 AM | finance.yahoo.com

MQS Management LLC Purchases New Position in United Therapeutics Corporation (NASDAQ:UTHR)

July 15 at 5:38 AM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by M&T Bank Corp

July 15 at 4:27 AM | marketbeat.com

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

July 14 at 7:16 PM | marketbeat.com

6,585 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Bought by Aurora Investment Counsel

July 14 at 6:41 AM | marketbeat.com

Emerald Advisers LLC Sells 1,061 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 14 at 5:41 AM | marketbeat.com

Morgan Stanley Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $328.00

July 13 at 2:03 AM | americanbankingnews.com

Nisa Investment Advisors LLC Sells 4,544 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 12, 2025 | marketbeat.com

United Therapeutics’ DeciPHer-ILD Study: A New Frontier in Pulmonary Hypertension Research

July 11, 2025 | tipranks.com

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

July 11, 2025 | zacks.com

Weil Company Inc. Buys 3,298 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 11, 2025 | marketbeat.com

1,822 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Acquired by Rehmann Capital Advisory Group

July 11, 2025 | marketbeat.com

UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)

July 10, 2025 | insidermonkey.com

J.P. Morgan Sticks to Their Buy Rating for United Therapeutics (UTHR)

July 10, 2025 | theglobeandmail.com

Morgan Stanley Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price

July 10, 2025 | marketbeat.com

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for Investors

July 9, 2025 | tipranks.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by TD Private Client Wealth LLC

July 9, 2025 | marketbeat.com

World Investment Advisors Has $718,000 Stake in United Therapeutics Corporation (NASDAQ:UTHR)

July 9, 2025 | marketbeat.com

Teacher Retirement System of Texas Sells 1,343 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

NKTR, FGEN, UTHR, ALLK, and SAGE Company Descriptions

Allakos NASDAQ:ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

FibroGen NASDAQ:FGEN

$7.52 +0.20 (+2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$7.60 +0.09 (+1.13%)

As of 04:04 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Nektar Therapeutics NASDAQ:NKTR

$24.14 +0.34 (+1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$24.24 +0.11 (+0.43%)

As of 06:43 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Sage Therapeutics NASDAQ:SAGE

$9.13 -0.04 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$9.11 -0.02 (-0.22%)

As of 06:51 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

United Therapeutics NASDAQ:UTHR

$298.16 +4.92 (+1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$298.12 -0.04 (-0.01%)

As of 06:46 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time